OR WAIT null SECS
The FDA has cleared MicroDental Laboratories’ MicrO2 Obstructive Sleep Apnea device, which features a patent-pending design and precision milling production process.
The FDA has cleared MicroDental Laboratories’ MicrO2Obstructive Sleep Apnea device, which features a patent-pending design and precision milling production process.
Also the MicrO2utilizes a PMMA material that is cured under controlled conditions, which reportedly allows the device to be compact yet strong, precise and predictable.
“Dentists are the front line for screening and managing patients with Obstructive Sleep Apnea,” said Kim Bradshaw, CEO and President of MicroDental Laboratories. “Many of our partner dentists asked for a small, precise, and easy to use Obstructive Sleep Apnea device. The MicrO2 device has been designed, from the very beginning, with these goals in mind.”
Another feature of the MicrO2is its approach to tritration that is said to be intended to make the device easier for both the dentist and the patient to use.
“The MicrO2 does not require patients to manage any mechanical adjustments, such as turning screws, or changing positions with elastics. Instead the MicrO2 comes with one pair of Upper and Lower arches set to the prescription, and a second pair set in any amount of advancement increments. Advancements are easily achieved by simply removing the current Upper or Lower arch device and inserting the next advancement device in the MicrO2 series,” commented Laura Sheppard, Sr. Director of Compliance and Regulatory Affairs for MicroDental.
Affecting over 18 million Americans, OSA is linked to snoring, memory loss, headaches, depression, as well as an increased risk of stroke, heart problems and motor vehicle accidents.
For more information about the MicrO2device, or to get additional details on sending cases, call 1-800-229-0936 or head to www.microdental.com.